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CancerAbstract Background: Epidermal growth factor receptor (EGFR) is frequently mutated in
various types of cancer. Although all oncogenic mutations are considered activating, different
tumour types have different mutation spectra. It is possible that functional differences underlie
this tumour-type speciﬁc mutation spectrum.
Methods: We have determined whether speciﬁc mutations in EGFR (EGFR, EGFRvIII and
EGFR-L858R) have differences in binding partners, differences in downstream pathway acti-
vation (gene expression and phosphoproteins), and have functional consequences on cellular
growth and migration.
Results: Using biotin pulldown and subsequent mass spectrometry we were able to detect
mutation speciﬁc binding partners for EGFR. Differential binding was conﬁrmed using a
proximity ligation assay and/or Western Blot for the dedicator of cytokinesis 4 (DOCK4),
UDP-glucose glycoprotein glucosyltransferase 1 (UGGT1), MYC binding protein 2
(MYCBP2) and Smoothelin (SMTN). We also demonstrate that each mutation induces the
expression of a speciﬁc set of genes, and that each mutation is associated with speciﬁc phos-
phorylation patterns. Finally, we demonstrate using stably expressing cell lines that EGFRvIII
and EGFL858R display reduced growth and migration compared to EGFR wildtype express-
ing cells.ds. Tel.:
894 L. Erdem-Eraslan et al. / European Journal of Cancer 51 (2015) 893–903Conclusion: Our results indicate that there are distinct functional differences between different
EGFR mutations. The functional differences between different mutations argue for the devel-
opment of mutation speciﬁc targeted therapies.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
The epidermal growth factor receptor (EGFR) is a
receptor tyrosine kinase that is a member of the ERBB
protein family and is localised on the cell membrane.
The receptor is activated by members of the epidermal
growth factor (EGF) family (a.o. EGF, amphiregulin,
TGF-a, HB-EGF and epiregulin) and binding of one
such ligand results in receptor dimerisation which
induces receptor phosphorylation, recruitment of adap-
tor proteins and subsequent activation of signal trans-
duction cascades [1,2].
Somatic mutations in the EGFR gene are found in
several types of cancer and the mutation spectrum
includes gene ampliﬁcations, gene-fusions, deletions in
the extracellular domain (e.g. EGFRvIII; a deletion of
exons 2–7), deletions in the intracellular domain (e.g.
EGFRvV; a deletion of exons 25–28) and mutations
aﬀecting the tyrosine kinase domain (mainly exon 19
and codon L858) [3–5]. These mutations result in a con-
stitutively activated isoform of the protein and con-
tribute to oncogenic transformation [5–8].
Although EGFR mutations are activating, there are
marked diﬀerences in the spectrum of mutations
between tumour types. For example, the c.2573T>G
missense mutation, resulting in the L858R substitution,
is found in 10–15% of all pulmonary adenocarcino-
mas [4]. This mutation is the most frequent of all muta-
tions in EGFR but has thus far never been identiﬁed in
glioblastomas (GBMs) [3]. The most common muta-
tions in GBMs aﬀect the extracellular domain of
EGFR, including EGFRvIII (30% of all GBMs) and
the A289V and V598V missense mutations [3]. These
extracellular domain mutations are not found in pul-
monary adenocarcinomas [4]. One of the explanations
for these tumour-type speciﬁc mutations is that each
mutation invokes a unique signal transduction cascade.
Indeed, EGFRvIII and EGFRwt have diﬀerential acti-
vation of the JNK, STAT and MAPK signalling path-
ways and induce the expression of a unique set of
genes [9–13]. Because diﬀerent tumour types may be
dependent on the unique pathways that are activated
by diﬀerent EGFR mutations, studying these functional
diﬀerences between mutations may identify novel,
tumour type speciﬁc treatment targets. Here, we have
further evaluated diﬀerential activation of signal trans-
duction pathways by EGFR-wt, EGFR-L858R and
EGFRvIII.2. Methods
EGFRvIII and EGFR-L858R cDNAs were obtained
from Addgene (Cambridge, MA), EGFR wildtype was
a gift from Ton van Agthoven and cloned into
pcDNA3.1/CT-GFP-TOPO (Invitrogen, Bleiswijk, the
Netherlands). A biotin tag and eGFP were inserted
C-terminal to the transmembrane domain of EGFR to
retain the integrity of the C-terminal (intracellular)
domain of EGFR. To demonstrate functionality, we
transfected EGFRbio-GFP into ZR-75-1 cells.
Normally, ZR-75-1 cells do not proliferate in the pres-
ence of tamoxifen [43]. However, ZR-75-1 cells express-
ing EGFR-bioGFP, cultured in the presence of
tamoxifen, responded to EGF stimulation by an
increase in cell proliferation, demonstrating the con-
struct remained functional (not shown). Stably trans-
fected HOG (human oligodendroglioma cells [44]) cell
lines were created by transfection, geneticin selection
and FACS sorting. Stable cell lines were derived from
bulk culture and not form a single sorted cell followed
by clonal propagation.
Migration and proliferation assays were performed
using an Incucyte (Essen Bioscience, Ann Arbor, MI).
For proliferation experiments, 50,000 cells/well were
plated in a 24-well Greiner plate (Greiner Bio-One,
Alphen a/d Rijn, the Netherlands). Growth curves were
constructed using the Conﬂuence v1.5 metric of the
Incucyte software. For migration experiments, cells were
grown to conﬂuence in a 24-well Essen ImageLockplate
after which a cell-free zone (scratch) was created using a
WoundMaker. Wells were then cultured in serum-free
media.
Constructs containing EGFRwt-BG, EGFRvIII-BG and
EGFRL858R-BG were transfected into HEK cell lines
using Polyethylenimine ‘Max’ (Polysciences,
Eppelheim, Germany). The EGFRwt-BG, EGFRvIII-BG
and EGFRL858R-BG proteins were then isolated using
Dynabeads (Life Technologies, Carlsbad, CA, United
States of America (USA)) as described previously [39].
Puriﬁed proteins were washed and loaded on a SDS
page gel. Nanoﬂow LC-MS/MS analysis was performed
essentially as described by van den Berg et al. [45].
Candidate binding proteins that were present in a
GFP control pulldown or identiﬁed in >10% of
CRAPome experiments were omitted from the analysis
[14]. We focused on candidate binding proteins that
were identiﬁed with MASCOT scores >300.
Table 1
Proteins showing selective binding to one or more speciﬁc Epidermal
growth factor receptor (EGFR) mutations.
Symbol EGFR wt EGFR V111 EGFR-p.L858R
AP1B1 961
CRKL 561 740 229
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Antibodies used were DOCK4 (1:100), UGGT1
(1:100), DDX21 (1:500) all from Sigma–Aldrich
(Zwijndrecht, the Netherlands), EGFR (1:1000, Cell
Signaling, Boston, MA) and GFP (1:5000, Abcam,
Cambridge, United Kingdom (UK)).
Cells (HOG, U87MG, HEK) were cultured on glass
slides for immunocytochemistry. Glioma samples were
obtained from the Erasmus MC glioma tissue bank.
Use of patient material for current study was approved
by the Institutional Review Board. Antibodies used for
immunocytochemistry and/or proximity ligation assays
were EGFR (1:200, DAKO, Heverlee, Belgium) and
DOCK4 (1:100), MYCBP2 (1:200) and SMTN1
(1:100) all from Abcam. Proximity ligation assays were
performed using a Duolink (Sigma–Aldrich) kit accord-
ing to the manufacturer’s instructions.
HEK cells were transiently transfected with EGFR-
bioGFP, EGFRL858R-bioGFP and EGFRvIII-bioGFP or
BIO-eGFP constructs. Twenty hours after transfection,
cells were FACS sorted to select for eGFP expressing
cells. Cells were then snap frozen in liquid nitrogen
and stored at 80 C. RNA extraction was performed
using TriZol (Invitrogen) and checked for RNA quality
on a Bioanalyzer (Agilent, Amstelveen, the
Netherlands). Gene expression was performed using
HU133 plus2 arrays (Aﬀymetrix, High Wycombe, UK)
run by AROS Applied Biotechnology (Aarhus,
Denmark). All experiments were performed in triplicate
with each replicate experiment performed on separate
days.
For reversed phase protein array (RPPA) analysis,
stably transfected HOG cells were plated in six well
plates and incubated in serum supplemented medium,
or serum depleted medium (24 h depletion) ± 200 ng
EGF for 5 min. RPPA arrays were performed by the
MD Anderson RPPA core facility. Luciferase activity
was measured by Dual–Luciferase Reporter Assay
System (Promega). Pathway analysis was performed
using Ingenuity (Redwood City, CA) and David [46].DNM2 462 798 211
DOCK4 2725 2136 536
EXOC7 533 213
IFI16 772 1079
IPO5 1403 411 217
LAD1 106 669 1056
LMO7 340 1362
MYCBP2 1606
MYO1E 156 503
NGLY1 353 1310 887
PIK3CA 147 902 86
PIK3CB 474 828 72
RTCB 558 341
SEL1L 604 174
SMTN 546
SPECC1L 69 909
SVIL 160 741
TNPO2 410 515
UBE3C 157 828 280
UGGT1 15733. Results
We ﬁrst generated constructs of wildtype EGFR and
of two common mutations, EGFRvIII and L858R, and
inserted a biotinylation tag and eGFP in-frame and C-
terminal to the transmembrane domain. Constructs are
referred to as EGFRwt-BG, EGFRvIII-BG and
EGFRL858R-BG respectively. Mass spectrometry follow-
ing pulldown of biotinylated constructs identiﬁed over
3000 candidate binding partners for at least one of these
constructs. When ﬁltering for duplicate hits, and
removal of proteins identiﬁed by a bio-eGFP control
pulldown or present in >10% of crapome pulldown
experiments [14], our list of candidate EGFR binding
proteins included 87 unique proteins (SupplementaryTable 1). Almost half (37/87) of these binding partners
are known interactors of EGFR and include CBL,
PIK3CA, PIK3R3, SHC1 and SOS1 [15–17].
Ingenuity pathway analysis indicated that the candi-
date EGFR associated proteins are involved in EGF sig-
nalling and Clathrin mediated endocytosis signalling.
Candidate EGFR interacting proteins are enriched for
proteins that are somatically mutated in GBMs. For
example, 7/87 (8.0%) genes are mutated at a population
frequency >1.5% (i.e. mutations found in at least 5/290
tumours) in the TCGA, a 3–4-fold enrichment com-
pared to all genes mutated at this frequency in GBMs
(485/20.000 genes, 2.4%, P = 0.007, Fishers’ exact
test).
Of the 87 candidate binding proteins, 22 showed
selective association to one of the EGFR constructs
(Table 1). Selective association was deﬁned as a relative
diﬀerence in mascot scores >3, and an absolute diﬀer-
ence in mascot scores >500 between any of the three
constructs. The strongest candidate proteins included
DOCK4 (dedicator of cytokinesis 4) UGGT1 (UDP-
glucose glycoprotein glucosyltransferase 1), MYCBP2
(MYC binding protein 2, E3 ubiquitin protein ligase)
and SMTN (Smoothelin).
Western blots on independent biotin pulldowns con-
ﬁrmed that DOCK4 binds preferentially to EGFRvIII-BG
and EGFRwt-BG but not to EGFRL858R-BG (Fig. 1b,
Western blot experiments in two independent experi-
ments). The association was further conﬁrmed using a
proximity ligation assay (PLA, Fig. 1c). DOCK4 also
associates with EGFR also under native conditions as
demonstrated by a co-immunoprecipitation using anti-
EGFR antibodies in non-transfected HEK cells
Fig. 1. EGFRwt-BG, EGFRvIII-BG or EGFRL858R-BG associate with speciﬁc proteins. (A) Mass spectrometry results for DOCK4 and UGGT1
showing diﬀerential binding to EGFR mutations. (B) Conﬁrmation of the mass spectrometry results by Western Blot on an independent pulldown.
(C) A proximity ligation assay conﬁrms that DOCK4 colocalises with EGFRwt-BG and EGFRvIII-BG but not with EGFRL858R-BG or Bio-GFP
control (not shown). All images taken at 63magniﬁcation. (D) Native EGFR also associates with DOCK4 as determined by immunoprecipitation
of EGFR. (E) A proximity ligation assay shows that DOCK4 and EGFR also colocalise in tumours.
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and EGFR are also colocalised in EGFR ampliﬁed
GBMs (Fig. 1e). DOCK4 remains associated withEGFR-wt in cells that were serum starved overnight fol-
lowed by EGF stimulation (Supplementary Fig. 1).
These data demonstrate that DOCK4 associates with
Fig. 2. EGFRwt-BG, EGFRvIII-BG or EGFRL858R-BG associate with
speciﬁc proteins. A proximity ligation assay shows that UGGT1
colocalises with EGFRwt-BG and EGFRvIII-BG but not with
EGFRL858R-BG or Bio-GFP control (see also Fig. 1B). Similarly,
MYCBP2 colocalises predominantly with EGFRvIII-BG whereas
SMTN predominantly colocalises with EGFRL858R-BG. All images
taken at 63 magniﬁcation.
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extent) with EGFRL858R-BG.
Because DOCK4 has been implicated in wnt pathway
activation [18] we screened for diﬀerential activation of
this pathway activation by the diﬀerent EGFR con-
structs. However, both under basal and under wnt acti-
vated conditions, no diﬀerences in wnt pathway
activation were identiﬁed (n = 3 independent experi-
ments, data not shown).
Mass spectrometry also highlighted that UGGT1
and MYCBP2 preferentially associate with EGFRvIII-
BG and that SMTN preferentially associates with
EGFRL858R-BG. PLA assays conﬁrmed the association
for all three proteins (Fig. 2), Western blot (WB) further
conﬁrmed the association of UGGT1 with EGFRvIII-BG
(Fig. 1b). It should be noted that some (minor) asso-
ciation of UGGT1, MYCBP1 and SMTN to other
EGFR constructs were found by PLA and/or WB.
We hypothesised that the selective association of dif-
ferent EGFR mutations ultimately would result in the
induction of a unique set of genes. We have therefore
performed gene expression proﬁling of cells expressing
EGFRwt-BG, EGFRvIII-BG, EGFRL858R-BG or BIO-
eGFP constructs (n = 3 per construct). Statistical analy-
sis of microarrays (SAM) identiﬁed 74, 109 and 187
probesets that were diﬀerentially expressed in EGFRwt-
BG, EGFRvIII-BG and EGFRL858R-BG expressing cell
lines compared to BIO-eGFP control (with diﬀerential
expression >2 and at a false discovery rate (fdr) <0.05,
Supplementary Table 2). These probesets correspond
to 61, 89 and 156 genes respectively. Many of these
genes are found in all three comparisons and are
involved in the transcription of DNA and are
signiﬁcantly enriched for the gene-ontology (GO) terms
‘sequence-speciﬁc DNA binding’, ‘transcription factor
activity’, ‘transcription regulator activity’, ‘DNA bind-
ing’ and ‘protein dimerization activity’ (all P < 0.001).
Top networks identiﬁed by Ingenuity pathway analysis
include ‘Cellular compromise, cellular function and
maintenance, gene expression’, ‘developmental disorder,
hereditary disorder, neurological disease’ and ‘neuro-
logical disease, cell-mediated immune response, cellular
development’.
To determine whether speciﬁc mutations have speciﬁc
gene-expression signatures, we performed SAM analysis
comparing gene expression between the diﬀerent EGFR
mutations. A total of 17, 12 and 35 probesets were iden-
tiﬁed that were diﬀerentially expressed between
EGFRwt-BG versus EGFRvIII-BG, EGFRwt-BG versus
EGFRL858R-BG and EGFRvIII-BG versus EGFRL858R-
BG respectively (with diﬀerential expression >2 and fdr
<0.2, Table 2, Fig. 3). These probesets correspond to
15, 11 and 26 diﬀerent genes respectively. Genes
speciﬁcally induced by EGFRvIII-BG expression include
SOCS3, C10ORF10 and DTX3L (10, 4, and 2-fold
induction respectively). EGFRL858R-BG speciﬁcallyinduces the expression of ARC, TFPI2, SGMS2,
ARLB5 and CCNA1 (8, 8, 3, 2 and 4-fold respective-
ly). Gene expression analysis therefore indicates that
Table 2
Probesets that are diﬀerentially expressed between EGFRwt-BG versus EGFRvIII-BG, EGFRwt-BG versus EGFRL858R-BG and EGFRvIII-BG versus
EGFRL858R-BG as identiﬁed by SAM analysis.
Gene_Symbol Probeset_ID eGFP EGFRwt EGFRvIII EGFR-p.L858R wt v vIII wt v L858R vIII v L858R
SOCS3 227697_at 4.5 4.9 9.1 5.6 X X
RAP1A 1555339_at 13.4 4.9 7.0 4.7 X X
C10orf10 209183_s_at 6.6 6.8 8.9 6.8 X X
Hs.527973 206359_at 4.3 4.6 6.6 4.9 X X
RAP1A 1555340_x_at 14.3 5.5 7.3 5.1 X X
XR_132893 1565830_at 6.0 4.6 6.0 5.0 X
SOCS2 203372_s_at 6.8 6.9 7.9 7.4 X
WDR78 1554140_at 6.5 5.1 6.5 5.7 X
DTX3L 225415_at 6.6 6.5 7.4 6.6 X
BC042589 235456_at 7.8 6.4 7.4 6.9 X
KIAA1267 224489_at 6.8 6.0 6.9 6.4 X
RAB30 229072_at 6.1 4.9 6.0 5.1 X
AK022645 232257_s_at 5.2 4.1 5.2 4.5 X
HSPA6 213418_at 4.8 8.2 6.7 9.3 X X
EGR1 201693_s_at 6.0 8.9 7.7 10.9 X X
EGR1 201694_s_at 8.2 11.2 10.2 12.6 X X
EGFR 210984_x_at 5.6 10.0 9.0 10.8 X
AKIRIN2 223143_s_at 5.1 5.0 5.8 6.1 X
ARC 210090_at 5.8 6.8 6.3 9.3 X
ARL5B 242727_at 5.9 6.1 6.0 7.3 X X
CCNA1 205899_at 3.9 4.5 3.9 5.9 X X
EGR3 206115_at 5.6 7.1 6.1 9.3 X X
FOS 209189_at 5.2 7.1 7.2 9.1 X
IL12A 207160_at 5.4 5.7 5.8 6.9 X
PHLDA1 217997_at 4.6 4.6 4.6 5.9 X
SGMS2 242963_at 5.1 5.1 5.1 6.5 X
TAC1 206552_s_at 4.8 6.7 6.0 8.2 X X
TFPI2 209277_at 3.6 4.1 3.6 6.3 X X
TFPI2 209278_s_at 5.4 6.6 5.6 8.7 X X
HSPA1L 210189_at 7.5 8.2 7.4 8.7 X
HSPH1 208744_x_at 9.4 9.7 9.2 10.3 X
DNAJB1 200666_s_at 9.4 10.8 9.9 11.8 X
LOC100652898 227404_s_at 6.5 9.5 8.4 10.7 X
INSIG1 201627_s_at 11.0 11.5 10.6 11.7 X
DUSP6 208891_at 6.0 8.1 7.6 8.6 X
DNAJB1 200664_s_at 8.2 9.6 8.7 10.7 X
ANXA1 201012_at 6.1 6.8 6.6 7.8 X
KCTD12 212188_at 8.9 9.7 8.9 10.7 X
HSPA6 117_at 5.4 7.0 6.0 7.9 X
DUSP6 208892_s_at 5.1 7.3 6.8 7.9 X
KCTD12 212192_at 9.8 10.2 9.7 10.8 X
ZCCHC12 228715_at 9.0 10.0 9.0 10.9 X
ETV5 203349_s_at 5.5 8.6 8.0 9.3 X
EGR2 205249_at 6.1 7.6 6.8 9.4 X
C11orf96 227099_s_at 8.5 10.3 9.5 12.0 X
GPR50 208311_at 7.2 8.0 7.2 9.1 X
DOK5 214844_s_at 4.4 5.1 4.5 6.0 X
INSIG1 201625_s_at 9.2 9.8 9.0 10.2 X
Diﬀerentially expressed genes (>2-fold change in expression level, fdr <0.2) between mutations are marked with X in one of the last three columns.
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We next analysed phosphoprotein levels by RPPA
arrays on HOG cells stably expressing EGFRwt-BG,
EGFRvIII-BG, EGFRL858R-BG or Bio-eGFP control.
Three conditions were examined: normal (serum supple-
mented cell culture), serum free and serum free, EGF
stimulated. All data are listed in Supplementary
Table 3. Analysis of EGFR on these arrays demon-
strates that all stably transfected cell lines, apart fromthe Bio-eGFP control, have increased levels of EGFR
and show increased EGFR phosphorylation on
pY1068 and pY1173. Serum deprivation does not result
in a loss of EGFR phosphorylation (pY1068 and
pY1173) which suggests that EGFR signalling remains
active under these conditions. Finally, EGF stimulation
results in a strong increase in EGFR_pY1068 (and to a
lesser extent in pY1173), predominantly in EGFRwt-BG
and EGFRL858R-BG expressing cells but also in BIO-
eGFP and expressing cells. EGF stimulation does not
Fig. 3. Genes that are diﬀerentially expressed between EGFRwt-BG
versus EGFRvIII-BG, EGFRwt-BG versus EGFRL858R-BG, and
EGFRvIII-BG versus EGFRL858R-BG as identiﬁed by SAM analysis.
Bio-eGFP control is included for reference. Scales are colour coded
from 13.0 (red), 7.0 (grey) to 4.5 (blue) as RMA expression values.
(For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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this mutation aﬀects the EGF binding domain.To determine whether speciﬁc mutations induce dif-
ferences in their downstream pathway activation, we
screened all proteins that showed a >2-fold change in
levels between diﬀerent constructs (Fig. 4). Examples of
diﬀerences identiﬁed include, under serum conditions
(i) lower levels of AKT-pT308 (and AKT_pS473) in
EGFRL858R-BG expressing HOG cells compared to
EGFRwt-BG, EGFRvIII-BG or BIO-eGFP expressing
cells; (ii) lower levels of MAPK_pT202 phosphorylation
in EGFRvIII-BG expressing cells compared to those
expressing EGFRwt-BG and EGFRL858R-BG. Virtually
identical data were obtained in an independent RPPA
experiment (Fig. 4, and Supplementary Fig. 2).
Western blot experiments (independently performed)
further conﬁrmed the diﬀerences in AKT-pT308 and
MAPK_pT202 phosphorylation (Fig. 4). These data
therefore indicate that diﬀerent mutations in EGFR
can induce a diﬀerential downstream pathway
phosphorylation.
Because our results indicate that each mutation has
unique molecular properties, we determined whether
the various forms of EGFR also diﬀerentially aﬀect cell
physiology. HOG cells stably expressing EGFRvIII-BG
and EGFRL858R-BG showed a decreased proliferation
compared to bio-eGFP or EGFRwt-BG expressing cells
(Fig. 5). The diﬀerences between constructs were consis-
tently observed over multiple experiments (n = 4 experi-
ments, six wells/experiment and four locations/well). In
a wound healing assay, the EGFRvIII-BG and
EGFRL858R-BG expressing HOG cells also had a sig-
niﬁcantly slower migration compared to bio-eGFP or
EGFRwt-BG expressing cells (P < 0.001, for all compar-
isons Fig. 5). The diﬀerence between constructs was con-
sistently observed in two independent experiments
(n = 2 experiments, six wells/experiment and three loca-
tions/well). These data therefore indicate that diﬀerent
mutations diﬀerentially aﬀect cell physiology.4. Discussion
In this study, we demonstrate diﬀerent mutations in
EGFR associate with diﬀerent proteins, activate unique
downstream signalling pathways (as shown by the
induction of a unique set of genes and protein phospho-
rylation) and that cell lines expressing diﬀerent EGFR
mutation constructs display diﬀerences in physiology
(proliferation and migration). Our data therefore
demonstrate that diﬀerent mutations have diﬀerent func-
tional consequences, which may provide an explanation
for a tumour type speciﬁc mutation spectrum.
Our data are in line with other studies that highlight-
ed diﬀerences between wildtype EGFR, EGFRvIII and/
or EGFR p.L858R. For example, wildtype EGFR and
EGFRvIII induce phosphorylation of diﬀerent sub-
strates, have diﬀerential activation of the JNK, STAT
and MAPK signalling pathways, induce the expression
Fig. 4. Proteins with >2-fold change in levels between diﬀerent constructs as determined by RPPA analysis. Shown are RPPA results of these
proteins in cells expressing EGFRwt-BG, EGFRvIII-BG, EGFRL858R-BG or Bio-eGFP control under normal cell culture conditions (serum
supplemented) and serum free cultures ± EGF. Colours are scaled from the minimum value (blue, 1.26), average (grey, 0.41) to max RPPA value
(red, 3.42). B) Conﬁrmation by an independent RPPA experiment of AKT-pT308 (left) and MAPK_pT202 (right). Results of the original (exp-1)
and conﬁrmation (exp-2) are shown. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
900 L. Erdem-Eraslan et al. / European Journal of Cancer 51 (2015) 893–903of a unique set of genes and have diﬀerences in nuclear
localisation [9–13,19]. Our data are also in line with a
study showing that both wtEGFR and EGFRvIIIinteract with DNA–Protein Kinase (PRKDC) whereas
EGFR p.L858R does not [19]: our biotin pulldown
showed a two fold reduction in association with
Fig. 5. Mutations in EGFR diﬀerentially aﬀect proliferation (top) and
migration (bottom) in HOG cells stably transfected with EGFRwt-BG,
EGFRvIII-BG, EGFRL858R-BG or Bio-eGFP control. EGFRvIII-BG and
EGFRL858R-BG have virtually identical migration.
L. Erdem-Eraslan et al. / European Journal of Cancer 51 (2015) 893–903 901PRKDC of EGFRL858R-BG compared to both EGFRwt-
BG and EGFRvIII-BG (Supplementary Table 1). We did
not observe diﬀerential association of EGFRwt-BG,
EGFRvIII-BG and EGFRL858R-BG with CBL proteins,
see [20]. However, binding to Cbl proteins occurs only
after stimulation with EGF, whereas our cells were not
EGF stimulated.
Apart from EGFR, a few proteins also show muta-
tion speciﬁc binding partners and diﬀerential activa-
tion of downstream signalling pathways. Examples
include TP53 (R273H and R267P) and PIK3CA
[21–24].
Because tumours often remain dependent on their
acquired genetic changes for growth, these changes are
direct targets for treatment. However, when each muta-
tion activates a unique set of downstream pathways, it is
possible each mutation will require speciﬁc inhibition.
Indeed, diﬀerent mutations in EGFR show diﬀerential
sensitivity towards inhibitors: activating mutation in
the kinase domain are associated with response to erlo-
tinib and geﬁtinib whereas the EGFR p.A289D muta-
tion is more sensitive to inhibition by lapatinib
[7,25,26]. Moreover, kinase domain mutations do not
occur in GBMs and inhibitors that act on these muta-
tions (erlotinib and geﬁtinib) do not show clinical beneﬁt
in GBM patients eventhough EGFR is a driver in
GBMs [27,28].Our experiments demonstrate that a number of pro-
teins diﬀerentially associate with EGFR constructs. It
is interesting to note that mutations in DOCK4,
UGGT1, MYCBP2 and SMTN have been found both
in GBMs (2/283, 4/283, 1/283 and 1/283 respectively)
and pulmonary adenocarcinomas (16/220, 7/220, 17/
220 and 4/220). The ﬁrst of these proteins that was fur-
ther examined, DOCK4, associates with EGFRvIII-BG
and, to a lesser extent, with EGFRwt-BG (but not with
EGFRL858R-BG). DOCK4 is mutated in various tumours
including bladder (10%), colorectal (10%) and lung
(7%). Two mutations in DOCK4 have thus far been
identiﬁed in GBMs. DOCK4 is involved in cell migra-
tion through the activation of RAC1 [29,30]. Whether
the diﬀerence in cell migration between EGFRwt-BG
and EGFRvIII-BG is due to diﬀerential association with
DOCK4 remains to be determined. DOCK4 also func-
tions as a scaﬀold protein within the Wnt signalling
pathway and is essential for activation of this pathway
in vivo [18]. However, we did not ﬁnd a mutation speciﬁc
activation of the WNT pathway.
A second diﬀerential binding protein, UGGT1, was
found to predominantly associate with EGFRvIII-BG.
UGGT1 plays a central role in the quality control of
protein folding in the endoplasmic reticulum (glycosy-
lated proteins) where it promotes substrate solubility
[31]. It was recently demonstrated that the L858R muta-
tion in EGFR reduces the disorganised conformation of
the protein [32]. Because UGGT1 is involved in the
quality control of protein folding, it is possible that
the lack of association between UGGT1 and
EGFRL858R-BG identiﬁed in our study may be a result
of an altered (i.e. less disorganised) conformation.
Similar to UGGT1, MYCBP2 also showed preferen-
tial association with EGFRL858R-BG. MYCBP2 encodes
an E3 ubiquitin ligase which mediates the ubiquitinyla-
tion and subsequent degradation of target proteins.
The protein is involved in the regulation of the mTOR
pathway: knockdown of MYCBP2 inhibits the mTOR
pathway [33]. Finally, SMTN showed preferential asso-
ciation with EGFRL858R-BG. SMTN co-localised with
a-actin and is involved in the contraction of smooth
muscle cells [34]. Whether the diﬀerential association
with speciﬁc EGFR mutations aﬀects the mTOR path-
way or actin dynamics in tumour cells remains to be
determined.
EGFR is a member of the ERBB protein family, a
family of proteins that plays a role in several cancer
types [35]. The various ERBB family members can het-
erodimerise with each other, and each heterodimer can
activate diﬀerent signal transduction pathways [35,36].
Although we demonstrate in this manuscript that diﬀer-
ent EGFR mutations activate unique molecular path-
ways, it remains to be determined whether the diﬀerent
mutations in EGFR also result in diﬀerent heterodimeri-
sation induced pathway activation. Of note, the various
902 L. Erdem-Eraslan et al. / European Journal of Cancer 51 (2015) 893–903ERBB family members do not overtly show a tumour
type speciﬁc mutation pattern [4,37].
Our results show that expression of EGFRvIII-BG or
EGFRL858R-BG in HOG cells results in a decreased pro-
liferation and migration, which may be counterintuitive
for an oncogene. However, such reduced proliferation
has been observed before in mutant melanoma cells
where expression of EGFR confers a growth disadvan-
tage that is further strengthened by the addition of
EGF [38]. Perhaps this is caused when an oncogene
(such as EGFR) is expressed in cells that have never
been dependent on the oncogene (or the various muta-
tions therein). A similar growth disadvantage (and
altered migration pattern) was observed when express-
ing mutant (R132H) IDH1 into cell lines [39,40].
Interestingly, IDH1 also has a tumour-type speciﬁc
mutation pattern [41,42].
In summary, our results indicate that there are dis-
tinct diﬀerences between diﬀerent mutations in EGFR.
Whether these diﬀerent mutations also have diﬀerent
oncogenic properties remains to be determined.
However, these functional diﬀerences can lead to the
identiﬁcation of mutation-speciﬁc EGFR inhibitors.Conﬂict of interest statement
None declared.Support
This work was supported by grants from the
Stichting Stophersentumoren.nl (2013), Erasmus MC
(mRACE pilot, 2012) and the Dutch Foundation for
Scientiﬁc Research ZonMw (Grants No. 95110051 and
92003560), Program Translational Research.
Appendix A. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at http://dx.doi.org/10.
1016/j.ejca.2015.02.006.References
[1] Weinberg RA. The Biology of Cancer: Garland Science; 2007.
[2] Citri A, Yarden Y. EGF-ERBB signalling: towards the systems
level. Nat Rev Mol Cell Biol 2006;7(7):505–16.
[3] Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr
H, Salama SR, et al. The somatic genomic landscape of
glioblastoma. Cell 2013;155(2):462–77.
[4] Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D,
et al. COSMIC: mining complete cancer genomes in the
Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res
2011;39(Database issue):D945–50.
[5] Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS.
Mechanisms for oncogenic activation of the epidermal growth
factor receptor. Cell Signal 2007;19(10):2013–23.[6] Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong
RA, et al. EGFR phosphorylates tumor-derived EGFRvIII
driving STAT3/5 and progression in glioblastoma. Cancer Cell
2013;24(4):438–49.
[7] Vivanco I, Robins HI, Rohle D, Campos C, Grommes C,
Nghiemphu PL, et al. Diﬀerential sensitivity of glioma- versus
lung cancer-speciﬁc EGFR mutations to EGFR kinase inhibitors.
Cancer Discov 2012;2(5):458–71.
[8] Holland EC, Hively WP, DePinho RA, Varmus HE. A consti-
tutively active epidermal growth factor receptor cooperates with
disruption of G1 cell-cycle arrest pathways to induce glioma-like
lesions in mice. Genes Dev 1998;12(23):3675–85.
[9] Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner
DD. Receptor dimerization is not a factor in the signalling
activity of a transforming variant epidermal growth factor
receptor (EGFRvIII). Biochem J 1997;324(Pt. 3):855–61.
[10] Antonyak MA, Moscatello DK, Wong AJ. Constitutive activa-
tion of c-Jun N-terminal kinase by a mutant epidermal growth
factor receptor. J Biol Chem 1998;273(5):2817–22.
[11] Pedersen MW, Pedersen N, Damstrup L, Villingshoj M, Sonder
SU, Rieneck K, et al. Analysis of the epidermal growth factor
receptor speciﬁc transcriptome: eﬀect of receptor expression level
and an activating mutation. J Cell Biochem 2005;96(2):412–27.
[12] Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L,
Sawaya R, et al. Analysis of phosphotyrosine signaling in
glioblastoma identiﬁes STAT5 as a novel downstream target of
DEGFR. J Proteome Res 2011;10(3):1343–52.
[13] Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S,
et al. Nuclear EGFRvIII-STAT5b complex contributes to
glioblastoma cell survival by direct activation of the Bcl-XL
promoter. Int J Cancer 2012;132:509–20.
[14] Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis
NA, Li T, et al. The CRAPome: a contaminant repository for
aﬃnity puriﬁcation-mass spectrometry data. Nat Methods
2013;10(8):730–6.
[15] Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L,
Winter A, Stark C, et al. The BioGRID interaction database: 2013
update. Nucleic Acids Res 2013;41(Database issue):D816–23.
[16] Foerster S, Kacprowski T, Dhople VM, Hammer E, Herzog S,
Saafan H, et al. Characterization of the EGFR interactome
reveals associated protein complex networks and intracellular
receptor dynamics. Proteomics 2013;13(21):3131–44.
[17] Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS,
Venugopal AK, et al. NetPath: a public resource of curated signal
transduction pathways. Genome Biol 2010;11(1):R3.
[18] Upadhyay G, Goessling W, North TE, Xavier R, Zon LI, Yajnik
V. Molecular association between beta-catenin degradation com-
plex and Rac guanine exchange factor DOCK4 is essential for
Wnt/beta-catenin signaling. Oncogene 2008;27(44):5845–55.
[19] Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translo-
cation modulates DNA repair following cisplatin and ionizing
radiation treatment. Cancer Res 2011;71(3):1103–14.
[20] Schmidt MH, Furnari FB, Cavenee WK, Bogler O. Epidermal
growth factor receptor signaling intensity determines intracellular
protein interactions, ubiquitination, and internalization. Proc
Natl Acad Sci U S A 2003;100(11):6505–10.
[21] Coﬃll CR, Muller PA, Oh HK, Neo SP, Hogue KA, Cheok CF,
et al. Mutant p53 interactome identiﬁes nardilysin as a
p53R273H-speciﬁc binding partner that promotes invasion.
EMBO Rep 2012;13(7):638–44.
[22] Vaughan CA, Frum R, Pearsall I, Singh S, Windle B, Yeudall A,
et al. Allele speciﬁc gain-of-function activity of p53 mutants in
lung cancer cells. Biochem Biophys Res Commun
2012;428(1):6–10.
[23] Ross RL, Askham JM, Knowles MA. PIK3CA mutation
spectrum in urothelial carcinoma reﬂects cell context-dependent
signaling and phenotypic outputs. Oncogene 2013;32(6):768–76.
L. Erdem-Eraslan et al. / European Journal of Cancer 51 (2015) 893–903 903[24] Pang H, Flinn R, Patsialou A, Wyckoﬀ J, Roussos ET, Wu H,
et al. Diﬀerential enhancement of breast cancer cell motility and
metastasis by helical and kinase domain mutations of class IA
phosphoinositide 3-kinase. Cancer Res 2009;69(23):8868–76.
[25] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto
RA, Brannigan BW, et al. Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-
small-cell lung cancer to geﬁtinib. N Engl J Med 2004;350(21):
2129–39.
[26] Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al.
EGFR mutations in lung cancer: correlation with clinical
response to geﬁtinib therapy. Science 2004;304(5676):1497–500.
[27] Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne
KL, et al. Phase II trial of geﬁtinib in recurrent glioblastoma. J
Clin Oncol 2004;22(1):133–42.
[28] van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC,
Kros JM, Carpentier AF, et al. Randomized phase II trial of
erlotinib versus temozolomide or carmustine in recurrent glioblas-
toma: EORTC brain tumor group study 26034. J Clin Oncol
2009;27(8):1268–74.
[29] Hiramoto K, Negishi M, Katoh H. Dock4 is regulated by RhoG
and promotes Rac-dependent cell migration. Exp Cell Res
2006;312(20):4205–16.
[30] Kobayashi M, Harada K, Negishi M, Katoh H. Dock4 forms a
complex with SH3YL1 and regulates cancer cell migration. Cell
Signal 2014;26(5):1082–8.
[31] Ferris SP, Jaber NS, Molinari M, Arvan P, Kaufman RJ. UDP-
glucose:glycoprotein glucosyltransferase (UGGT1) promotes sub-
strate solubility in the endoplasmic reticulum. Mol Biol Cell
2013;24(17):2597–608.
[32] Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror
RO, et al. Oncogenic mutations counteract intrinsic disorder in
the EGFR kinase and promote receptor dimerization. Cell
2012;149(4):860–70.
[33] Han S, Witt RM, Santos TM, Polizzano C, Sabatini BL, Ramesh
V. Pam (Protein associated with Myc) functions as an E3
ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal
2008;20(6):1084–91.
[34] Niessen P, Rensen S, van Deursen J, De Man J, De Laet A,
Vanderwinden JM, et al. Smoothelin-a is essential for functional
intestinal smooth muscle contractility in mice. Gastroenterology
2005;129(5):1592–601.[35] Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer:
the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol
2007;39(5):851–6.
[36] Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family:
not so prototypical receptor tyrosine kinases. Cold Spring Harb
Perspect Biol 2014;6(4):a020768.
[37] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA,
et al. The cBio cancer genomics portal: an open platform for
exploring multidimensional cancer genomics data. Cancer Discov
2012;2(5):401–4.
[38] Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C,
et al. Reversible and adaptive resistance to BRAF(V600E)
inhibition in melanoma. Nature 2014;508(7494):118–22.
[39] Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L,
Lamfers M, et al. IDH1 R132H decreases proliferation of glioma
cell lines in vitro and in vivo. Ann Neurol 2011;69(3):455–63.
[40] Wang JB, Dong DF, Wang MD, Gao K. IDH1 overexpression
induced chemotherapy resistance and IDH1 mutation enhanced
chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Asian Pac J Cancer Prev 2014;15(1):427–32.
[41] Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R,
Dubbink HJ, Dinjens W, et al. Segregation of non-p.R132H
mutations in IDH1 in distinct molecular subtypes of glioma. Hum
Mutat 2010;31(3):E1186–99.
[42] Schaap FG, French PJ, Bovee JV. Mutations in the isocitrate
dehydrogenase genes IDH1 and IDH2 in tumors. Adv Anat
Pathol 2013;20(1):32–8.
[43] van Agthoven T, Veldscholte J, Smid M, van Agthoven TL,
Vreede L, Broertjes M, et al. Functional identiﬁcation of genes
causing estrogen independence of human breast cancer cells.
Breast Cancer Res Treat 2009;114(1):23–30.
[44] Buntinx M, Vanderlocht J, Hellings N, Vandenabeele F,
Lambrichts I, Raus J, et al. Characterization of three human
oligodendroglial cell lines as a model to study oligodendrocyte
injury: morphology and oligodendrocyte-speciﬁc gene expression.
J Neurocytol 2003;32(1):25–38.
[45] van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K,
Demmers J, et al. An Oct4-centered protein interaction network
in embryonic stem cells. Cell Stem Cell 2010;6(4):369–81.
[46] Huang da W, Sherman BT, Lempicki RA. Systematic and
integrative analysis of large gene lists using DAVID bioinfor-
matics resources. Nat Protoc 2009;4(1):44–57.
